Share Name Share Symbol Market Type Share ISIN Share Description
Silence Ther. LSE:SLN London Ordinary Share GB00B9GTXM62 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +2.50p +2.29% 111.50p 108.00p 115.00p - - - 0.00 16:35:14
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -9.4 -10.4 - 59.25

Silence Therapeutics Share Discussion Threads

Showing 49951 to 49972 of 49975 messages
Chat Pages: 1999  1998  1997  1996  1995  1994  1993  1992  1991  1990  1989  1988  Older
DateSubjectAuthorDiscuss
30/11/2016
13:53
Thanks for this Waterloo but you could actually look at this as a positive for SLN in that the failure of their delivery mechanism just highlights the proven track record safety profile of SLN's delivery mechanisms.
callumross
30/11/2016
07:56
htTps://endpts.com/hot-on-the-heels-of-a-clinical-hold-arrowhead-torches-its-clinical-pipeline-slashes-staff/
waterloo01
15/11/2016
07:34
'Silence has confirmed the potential of its delivery platform for in vivo gene editing'... looks like a leap forward for Silence. Certainly very good news indeed
gersemi
15/11/2016
07:29
A bit technical for me, but that RNS sounds like good news...
1gw
06/10/2016
17:37
I don't think I'll be running just yet. "Safety problems have not shown up to date in the company's other RNAi drugs, which are all delivered into patients differently from revusiran, Maraganore said. He added that he still expects to have three drugs approved and on the market by 2020." ... but certainly a reminder of the other side of the coin for biotech from the SUMM experience.
1gw
06/10/2016
13:40
hTtps://www.thestreet.com/story/13843510/1/alnylam-gene-silencing-drug-blows-up-damage-could-spread-deep-into-biotech-sector.html Run?
waterloo01
05/10/2016
12:51
Decent volume today. Are we getting a bit of the SUMM slipstream?
1gw
04/10/2016
14:43
Well that's why we buy into biotech I suppose - hoping to get a new treatment through to commercialisation or have someone with deep pockets buy in to help progress a potential treatment. SLN's turn may come... In the meantime it can't do any harm to have a reminder of what can happen.
1gw
04/10/2016
12:28
Looking at todays announcement from SUMM, doesn't it just make you envious. Surely our turn will come!
callumross
29/9/2016
14:46
Canaccord Genuity today reaffirms its buy investment rating on Silence Therapeutics PLC (LON:SLN) and raised its price target to 249p (from 233p).
callumross
27/9/2016
11:16
I asked Ali M about the risk of costly legal battles at the AGM given the annual report statement that "the Company has received advice from three separate law firms indicating that the issued claims potentially capture other development stage siRNA candidates" as well as the disagreement over the milestone payment with Quark. I got the impression from him that the "legal opinions" statement wasn't as bad as it sounded (to me) and that this was largely a due diligence move to strengthen the case for seeking licensing fees as a result of the new patent granted. I can't remember the detail but I think perhaps the reason for "several" opinions is that there are several drugs they are hoping to bring within scope of their patents. And I am pleased to see from today's statement that the Quark issue has gone to arbitration rather than litigation.
1gw
27/9/2016
08:41
Long wavelength is right. Never liked Quark (and SLN seem to have a few issues as well) and talk of favourable legal opinions says to me they will have some court cases to fight. Nothing substantial in trials. I'll leave you with your deep base resonance.
waterloo01
27/9/2016
08:19
It's a fairly long wavelength business though, isn't it? I don't think we should expect to see dramatic new developments every few months. Even so, the section on licensing looks pretty positive to me: "In December 2015, the Company had a further patent (9,222,092) granted in the US, which substantially broadens its position in modified siRNA molecules and we continue to seek additional granted claims through a program of continuation filings. In the past six months Silence has obtained several favourable legal opinions indicating that multiple siRNA based drugs currently in clinical development potentially fall within its issued claims. Subsequently, the Company has invited the relevant companies to enter licensing negotiations. The strengthened position around AtuRNAi® makes this asset an even more significant value driver, comprising existing licensee Quark’s clinical progress, ongoing negotiations and potential additional licences."
1gw
27/9/2016
07:00
Seems like very little progress on any fronts since I last looked a year ago.
waterloo01
26/9/2016
15:10
Not in anymore, but has that much changed when aut027 was/is the companies lead and main trial? Never liked it when they went for combo.
waterloo01
26/9/2016
15:01
I've a feeling that it will be announced that atu027 has been discontinued but kind of already in the price, I suspect. Hopefully, other developments will more than counterbalance this.
callumross
26/9/2016
14:21
What chance things get a bit busier tomorrow with the interims?
1gw
09/9/2016
14:15
Nice to see another bounce today, this time on what looks like low volume. Not at all clear to me why it's bouncing though...
1gw
11/8/2016
09:02
Are we expecting any news now the price has picked up together with the volume?
beergut
09/8/2016
13:44
probably MTFB not being able to do a dual listing having an impact on sentiment but SLN dropped on such low volume I suspect there is nothing 'real' behind it
rogen83
09/8/2016
13:09
Any known reason for the drop this afternoon...
beergut
26/7/2016
19:15
Interesting read gersemi - thank you.
callumross
Chat Pages: 1999  1998  1997  1996  1995  1994  1993  1992  1991  1990  1989  1988  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:43 V: D:20161203 23:56:09